サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1768464

塞栓療法の世界市場

Embolotherapy

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.48円
塞栓療法の世界市場
出版日: 2025年07月11日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

塞栓療法の世界市場は2030年までに85億米ドルに達する見込み

2024年に54億米ドルと推定される塞栓療法の世界市場は、分析期間2024-2030年にCAGR 7.7%で成長し、2030年には85億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである塞栓剤は、CAGR 8.2％を記録し、分析期間終了時には67億米ドルに達すると予測されます。サポート機器セグメントの成長率は、分析期間中CAGR 5.8％と推定されます。

米国市場は14億米ドル、中国はCAGR 11.3％で成長予測

米国の塞栓療法市場は2024年に14億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに21億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.0％と7.1％と予測されています。欧州では、ドイツがCAGR 4.8%で成長すると予測されています。

世界の塞栓療法市場- 主要動向と促進要因のまとめ

塞栓療法は低侵襲治療にどのような革命を起こしているか？

最先端の低侵襲治療法である塞栓療法は、標的部位への血流を効果的に遮断することで、がん、血管異常、外傷による出血など、さまざまな複雑な症状の治療を促進し、医療の展望を再定義しています。当初は消化管出血や外傷の管理に使用されていたが、塞栓療法は大きく進化し、腫瘍学や女性の健康などの分野にも応用が広がっています。腫瘍学では、経動脈的化学塞栓療法（TACE）と放射性塞栓療法が肝がん治療に広く用いられており、腫瘍から血液供給を奪うと同時に局所的な化学療法を行い、周辺組織へのダメージを最小限に抑えています。同様に、子宮筋腫塞栓術は、非外科的な解決策を求める女性にとって、子宮摘出術に代わる、侵襲が少なく、回復が早い方法として好まれています。これらの分野にとどまらず、塞栓療法は、静脈瘤の治療、動脈奇形の管理、緊急外傷症例における出血のコントロールなどでもよく使われるようになり、ヘルスケア提供者に、複雑なシナリオにおける効率的で、しばしば救命的な選択肢を提供しています。

塞栓療法は、その主な用途以外にも、従来の外科的処置の理想的な候補者ではないハイリスク患者を管理する能力で認められています。その低侵襲性により、合併症のリスクを軽減し、入院期間を短縮し、回復時間を短縮することができます。この治療法は、外来でも集中治療室でも、個々の患者のニーズに合わせることができる汎用性があるため、ヘルスケア提供者の間でその魅力が広がっています。さらに、外傷の場合、塞栓療法の迅速な展開と内出血の正確なコントロールは、さらなる介入のために患者を安定させることができます。このような利点から、塞栓療法はインターベンショナル・ラジオロジーにおいて極めて重要な技術であり続けており、患者中心のケアに重点を置いた複雑な病状の管理において、ますます重要な役割を果たすと予測されています。

塞栓療法を前進させる技術的進歩とは？

画像処理とカテーテルシステムにおける最近の技術革新は、塞栓療法を新たな高みへと押し上げ、手技をより安全で正確なものにし、様々な臨床現場においてますます効果的なものにしています。高精細透視、MRIガイド下インターベンション、3D画像などの画像診断の進歩により、医療従事者は標的部位を驚くほど詳細に可視化することができ、塞栓剤を正確に投与し、周囲の健康な組織への影響を最小限に抑えることができます。このようなイメージングの向上とともに、塞栓物質自体も進化しており、薬剤溶出性ビーズや生分解性ミクロスフェアのような革新的なオプションは、2つの利点を提供しています。これらの先端材料は、血流を遮断すると同時に、局所的な薬物療法を時間をかけて行い、腫瘍やその他の複雑な病態を治療するためのより包括的なアプローチを可能にします。イメージング技術と先端材料の組み合わせは、患者の予後を著しく向上させ、塞栓療法の応用可能性を広げます。

もうひとつの主な発展はカテーテル技術の進化であり、マイクロカテーテルやステアラブルカテーテルの新設計により、複雑な血管網内でのナビゲーションが向上しました。このレベルの制御は、脳のような敏感な部位の腫瘍や異常な血管を標的にするような、ピンポイントの正確さが要求される手技には不可欠です。さらに、ロボット支援による塞栓療法は新たなトレンドであり、臨床医は複雑な手技をより正確に、放射線被曝を低減しながら行うことができます。人工知能（AI）と機械学習を塞栓療法に統合することも視野に入っており、治療結果の予測的洞察を提供し、カスタマイズされた治療計画を導くことができます。これらの技術的進歩を総合すると、塞栓療法は高精度で効果的な治療オプションへと変貌を遂げ、進化する現代ヘルスケアの要求に応え、低侵襲治療の可能性を広げています。

なぜ塞栓療法の新しい最終用途が出現しているのでしょうか？

塞栓療法の適用範囲は、様々な治療領域で急速に拡大しています。その主な理由は、低侵襲性であり、到達困難な病態の治療に有効だからです。例えば腫瘍学では、この手技は肝臓がんだけでなく、腎臓がん、前立腺がん、その他の種類の腫瘍にも有効であることが証明されており、患者に従来の手術に代わる、より低侵襲で副作用の少ない選択肢を提供しています。この手技は外傷治療でも一般的になってきており、内出血を抑えることができるため、他の外科的介入を行う前に患者を安定させるのに重要な手段となっています。女性の健康分野では、塞栓療法は子宮筋腫塞栓術のような手技で支持を集めており、子宮摘出術に代わる、回復が早くリスクの少ない非手術的な解決策を求める患者にアピールしています。これらの用途は、塞栓療法が複数の医療分野で基礎治療となる可能性を強調しています。

塞栓療法の多用途性は、動静脈奇形（AVM）の治療や、異常な血流を調整することによる動脈瘤の予防など、心臓血管への応用にも及んでいます。個別化医療が成長し続ける中、この治療法の適応性は、患者固有のニーズに合わせることを可能にし、塞栓剤と標的療法を組み合わせる可能性を提供します。このような個別化アプローチは、臨床医が個々の患者プロファイルに合わせた処置を行うことができるため、治療領域のさらなる拡大を支えるものと期待されます。さらに、塞栓療法は、その精度と最小限の侵襲性からデリケートな構造に適しているため、消化器系や泌尿器系の治療にも応用されつつあります。この技術が広く採用されることで、患者の予後が改善されるだけでなく、ヘルスケアプロバイダーは、ますます多様化する病状に対して高度な治療オプションを提供できるようになり、塞栓療法が現代のインターベンショナル医療において重要な役割を果たすようになっています。

塞栓療法の世界市場成長の原動力は？

塞栓療法市場の成長は、主に技術の進歩、最終用途の拡大、ヘルスケアの嗜好の進化に根ざしたいくつかの要因によって牽引されています。高精細画像や洗練されたカテーテルデザインなどの技術革新により、手技の精度が向上し、塞栓療法はさまざまな治療分野で信頼できる選択肢となっています。このことは特に腫瘍学に関連しており、この手技の低侵襲性と腫瘍ターゲティングの有効性により、特に肝臓がんや腎臓がんの症例で採用が増加しています。さらに、薬剤溶出性および生分解性塞栓剤の開発により治療の幅が広がり、血液供給を遮断し局所的な薬物療法を行う二重作用のアプローチが可能になりました。

最終用途の拡大も市場成長に重要な役割を果たしており、塞栓療法は外傷治療、女性の健康、心臓血管への応用、さらには泌尿器科や消化器科のような新興分野での使用も増えています。さらに、患者中心の医療への動向と低侵襲手術への需要の高まりは、患者が回復時間の短縮と合併症リスクの低い代替医療を求めるようになっているため、さらに普及を後押ししています。人口の高齢化と、がんや血管障害を含む慢性疾患の罹患率の上昇が、効果的で的を絞った介入としての塞栓療法の需要を下支えしています。ヘルスケアプロバイダーとメーカーの戦略的協力関係も、イノベーションを促進し、特に新興市場において先進的なソリューションを世界的に利用しやすくすることで、市場の成長を支えています。これらの要因が相まって、塞栓療法は技術革新、アプリケーションの拡大、現代ヘルスケアにおける精密で低侵襲な治療へのシフトを原動力として、持続的な成長を遂げようとしています。

セグメント

製品セグメント（塞栓剤、サポートデバイス）;適応疾患（がん、末梢血管疾患、神経疾患、泌尿器・腎臓疾患、消化器疾患）

調査対象企業の例

  • Abbott Laboratories
  • Acandis GmbH
  • Balt Extrusion
  • Boston Scientific Corporation
  • BTG PLC
  • Cook Medical
  • Johnson & Johnson
  • Kaneka Corporation
  • Medtronic PLC
  • Meril Life Sciences Pvt., Ltd.
  • Merit Medical Systems
  • Penumbra, Inc.
  • Sirtex Medical Limited
  • Stryker Corporation
  • Terumo Corporation

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP21718

Global Embolotherapy Market to Reach US$8.5 Billion by 2030

The global market for Embolotherapy estimated at US$5.4 Billion in the year 2024, is expected to reach US$8.5 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Embolic Agents, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$6.7 Billion by the end of the analysis period. Growth in the Support Devices segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 11.3% CAGR

The Embolotherapy market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 11.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.8% CAGR.

Global Embolotherapy Market - Key Trends & Drivers Summarized

How Is Embolotherapy Revolutionizing Minimally Invasive Treatments?

Embolotherapy, a cutting-edge minimally invasive procedure, is redefining the landscape of medical treatments by effectively blocking blood flow to targeted areas, facilitating treatment for a variety of complex conditions such as cancer, vascular anomalies, and trauma-related bleeding. Initially employed to manage gastrointestinal bleeding and traumatic injuries, embolotherapy has evolved significantly, with applications expanding to fields like oncology and women’s health. In oncology, transarterial chemoembolization (TACE) and radioembolization are widely used for liver cancer treatment, depriving tumors of blood supply while delivering localized chemotherapy, minimizing damage to surrounding tissues. Similarly, uterine fibroid embolization has emerged as a preferred alternative to hysterectomy for women seeking non-surgical solutions, offering a less invasive, quicker recovery pathway. Beyond these areas, embolotherapy has become a popular choice in treating varicose veins, managing arterial malformations, and controlling bleeding in emergency trauma cases, providing healthcare providers with an efficient and often life-saving option in complex scenarios.

Beyond its primary applications, embolotherapy is recognized for its ability to manage high-risk patients who may not be ideal candidates for traditional surgical procedures. With its minimally invasive nature, the procedure reduces the overall risk of complications, shortens hospital stays, and decreases recovery time, factors that resonate with patient preferences for treatment. The procedure’s versatility allows it to be tailored to individual patients’ needs, whether in outpatient settings or within intensive care environments, which has broadened its appeal among healthcare providers. Additionally, in trauma cases, embolotherapy’s rapid deployment and precision in controlling internal bleeding can stabilize patients for further interventions. Given these benefits, embolotherapy continues to be a pivotal technique within interventional radiology and is projected to play an increasingly prominent role in managing complex medical conditions with a focus on patient-centered care.

What Technological Advancements Are Propelling Embolotherapy Forward?

Recent technological breakthroughs in imaging and catheter systems are propelling embolotherapy to new heights, making procedures safer, more precise, and increasingly effective across various clinical settings. Imaging advancements, such as high-definition fluoroscopy, MRI-guided intervention, and 3D imaging, allow healthcare providers to visualize target areas with remarkable detail, ensuring embolic agents are precisely deployed and minimizing impact on surrounding healthy tissue. Alongside these imaging enhancements, embolic materials themselves have evolved, with innovative options like drug-eluting beads and biodegradable microspheres offering dual benefits. These advanced materials block blood flow while simultaneously delivering localized drug therapy over time, enabling a more comprehensive approach to treating tumors and other complex conditions. The combination of imaging technology and advanced materials significantly enhances patient outcomes and broadens the potential applications of embolotherapy.

Another key development is the evolution of catheter technology, with new designs in micro and steerable catheters improving navigation within intricate vascular networks. This level of control is essential in procedures requiring pinpoint accuracy, such as those targeting tumors or abnormal blood vessels in sensitive areas like the brain. Additionally, robotic-assisted embolotherapy is an emerging trend, allowing clinicians to perform complex procedures with increased precision and reduced radiation exposure. The integration of artificial intelligence (AI) and machine learning in embolotherapy is also on the horizon, offering predictive insights into procedure outcomes, which can guide customized treatment plans. Collectively, these technological advancements are transforming embolotherapy into a highly precise, effective treatment option, meeting the evolving demands of modern healthcare and expanding the possibilities for minimally invasive interventions.

Why Are New End-Use Applications for Embolotherapy Emerging?

The scope of embolotherapy is rapidly expanding across a variety of therapeutic areas, largely due to its minimally invasive nature and effectiveness in treating hard-to-reach conditions. In oncology, for example, the procedure has proven effective not only for liver cancer but also for renal, prostate, and other types of tumors, offering patients less invasive alternatives to traditional surgery with fewer side effects. This technique is also becoming more common in trauma care, where its capacity to control internal bleeding makes it a critical tool in stabilizing patients before other surgical interventions. In women’s health, embolotherapy is gaining traction with procedures like uterine fibroid embolization, providing a non-surgical solution that appeals to patients seeking alternatives to hysterectomy, with quicker recovery times and less risk involved. These applications highlight embolotherapy’s potential to become a cornerstone treatment in multiple medical fields.

The versatility of embolotherapy extends to cardiovascular applications, where it is used to treat arteriovenous malformations (AVMs) and prevent aneurysms by regulating abnormal blood flow. As personalized medicine continues to grow, the procedure's adaptability enables it to align with patient-specific needs, offering the possibility of combining embolic agents with targeted therapies. This personalized approach is expected to support further expansion in treatment areas, as clinicians can tailor procedures to individual patient profiles. Additionally, embolotherapy is seeing applications in gastrointestinal and urological treatments, as its precision and minimal invasiveness make it suitable for delicate structures. The broader adoption of this technique is not only improving patient outcomes but also enabling healthcare providers to offer advanced treatment options across an increasing array of medical conditions, reinforcing embolotherapy’s role as a critical tool in modern interventional medicine.

What’s Driving the Growth of the Global Embolotherapy Market?

The growth in the embolotherapy market is driven by several factors, primarily rooted in technological advancements, expanding end-use applications, and evolving healthcare preferences. Technological innovations such as high-definition imaging and sophisticated catheter designs have enhanced procedural precision, making embolotherapy a reliable choice across various therapeutic fields. This is particularly relevant in oncology, where the procedure’s minimally invasive nature and effectiveness in tumor targeting have led to increased adoption, especially in cases of liver and renal cancers. Furthermore, the development of drug-eluting and biodegradable embolic agents has broadened the scope of treatments, allowing for dual-action approaches that block blood supply and deliver localized drug therapy, a feature gaining traction in the oncology sector.

End-use expansion also plays a significant role in market growth, with embolotherapy being increasingly used in trauma care, women's health, cardiovascular applications, and even emerging fields like urology and gastroenterology. Additionally, the trend towards patient-centered healthcare and the growing demand for minimally invasive procedures are further fueling adoption, as patients increasingly seek alternatives with shorter recovery times and lower complication risks. An aging population and rising incidence of chronic diseases, including cancer and vascular disorders, underpin the demand for embolotherapy as an effective, targeted intervention. Strategic collaborations between healthcare providers and manufacturers also support market growth by fostering innovation and making advanced solutions more accessible globally, especially in emerging markets. Together, these factors are positioning embolotherapy for sustained growth, driven by innovation, expanding applications, and a shift towards precision and minimally invasive treatments in modern healthcare.

SCOPE OF STUDY:

The report analyzes the Embolotherapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Segment (Embolic Agents, Support Devices); Disease Indication (Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders, Gastrointestinal Disorders)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Acandis GmbH
  • Balt Extrusion
  • Boston Scientific Corporation
  • BTG PLC
  • Cook Medical
  • Johnson & Johnson
  • Kaneka Corporation
  • Medtronic PLC
  • Meril Life Sciences Pvt., Ltd.
  • Merit Medical Systems
  • Penumbra, Inc.
  • Sirtex Medical Limited
  • Stryker Corporation
  • Terumo Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Global Economic Update
    • Embolotherapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Cancer and Vascular Disorders Expands the Addressable Market for Minimally Invasive Embolotherapy Solutions
    • Increasing Adoption of Minimally Invasive Medical Interventions Spurs Growth in Embolotherapy Techniques Across Key Healthcare Markets
    • Technological Advancements in Embolic Agents Improve Precision and Effectiveness, Driving Broader Adoption of Embolotherapy Solutions
    • Expanding Geriatric Population with Increased Risk of Vascular and Cancer-Related Conditions Propels Market Demand for Embolotherapy Procedures
    • Growing Awareness of Uterine Fibroid Embolization as a Non-Surgical Alternative to Hysterectomy Strengthens the Market for Womens Health Applications
    • Rising Prevalence of Arteriovenous Malformations (AVMs) Drives the Need for Specialized Embolotherapy Solutions to Treat Complex Vascular Malformations
    • Shift Toward Outpatient and Ambulatory Care Settings for Embolotherapy Procedures Expands Access and Drives Cost-Effective Healthcare Delivery
    • Growing Use of Embolization Techniques as Less Invasive Alternatives to Open Surgery in Trauma Cases Boosts Demand for Specialized Embolotherapy Solutions
    • Improved Biocompatibility of Next-Generation Embolic Materials Expands Usage in Multi-Therapeutic Applications, Including Oncology and Gynecology
    • Innovations in Catheter Technologies and Delivery Systems Improve Precision and Safety of Embolotherapy Procedures, Supporting Market Growth
    • Increased Adoption of Drug-Eluting Beads in Embolotherapy Enhances Efficacy in Cancer Treatment, Creating New Growth Opportunities in Oncology
    • Rising Global Healthcare Expenditures and Improved Access to Quality Care Drive Demand for Embolotherapy Solutions in Developed and Emerging Markets
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Embolotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Embolic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Embolic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Embolic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Support Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Support Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Support Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Peripheral Vascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Peripheral Vascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Peripheral Vascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Urological & Nephrological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Urological & Nephrological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Urological & Nephrological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Gastrointestinal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Gastrointestinal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Embolotherapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • JAPAN
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • CHINA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • EUROPE
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Embolotherapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • FRANCE
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • GERMANY
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Embolotherapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • INDIA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Embolotherapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Embolotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Embolotherapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Embolotherapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030
  • AFRICA
    • Embolotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Embolotherapy by Product Segment - Embolic Agents and Support Devices - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Embolotherapy by Product Segment - Embolic Agents and Support Devices Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Embolotherapy by Product Segment - Percentage Breakdown of Value Sales for Embolic Agents and Support Devices for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Embolotherapy by Disease Indication - Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Embolotherapy by Disease Indication - Percentage Breakdown of Value Sales for Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological & Nephrological Disorders and Gastrointestinal Disorders for the Years 2015, 2025 & 2030

IV. COMPETITION